Drugs / ACAM3000
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00079820 | Apr 2004 → Oct 2006 | smallpox | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00466245 | Jul 2005 → Jun 2006 | smallpox | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACAM3000 | “ACAM3000 MVA Smallpox Vaccine” NCT00466245 ↗ |
| Known as | MVA Smallpox Vaccine | “ACAM3000 MVA Smallpox Vaccine” NCT00466245 ↗ |
| Modality | Vaccine | “investigational vaccine” NCT00079820 ↗ |
| Route | Subcutaneous | “Two 0.5mL subcutaneous injections, separated by 28 days” NCT00466245 ↗ |